Chief Operating Officer, Redcare Pharmacy
Shop Apotheke wird Redcare Pharmacy: CFO Jasper Eenhorst und COO Theresa Holler im Talk
Weitere Videos findet Ihr unter: https://www.deraktionaer.tv
Shop Apotheke heisst jetzt Redcare Pharmacy. Was ist in Zukunft von dem Unternehmen zu erwarten?
Anlässlich des Rebrandings der Shop Apotheke Europe zu Redcare Pharmacy fand eine Opening Bell-Veranstaltung an der Frankfurter Börse statt. Im Rahmen des Events konnte DER AKTIONÄR TV mit CFO und COO des frisch umbenannten Unternehmens reden. Warum der neue Name, welches Wachstum ist zu erwarten und was verspricht man sich vom E-Rezept? Darüber sprechen CFO Jasper Eenhorst und COO Theresa Holler im Interview mit DER AKTIONÄR TV Moderat...
Transcript (15 segments)
H
Host0:07
Dear viewers, Shop-Apotheke is no longer heating up, but Redcare Pharmacy. Today, on the occasion of this renaming, there was a festive opening at the Berlin Stock Exchange, and I am very pleased that two company representatives are now with me. I warmly welcome Theresa Holler from Redcare Pharmacy and Jasper Ainhorst, the CFO of what was formerly Shop-Apotheke and now Redcare Pharmacy. You have to get used to the name, Ms. Holler, so my first question to you: why the renaming?
T
Theresa Holler0:36
We have partly already gotten used to it because a renaming, you can imagine, doesn't happen overnight. Of course, now here it's an overnight renaming at the stock exchange, but it's a long process. That means it's one, two, three, four years of thinking about which name, then checking if all the domains are free. And for us, it's important that we are not just a shop. We are clearly a pharmacy, so 'pharmacy' remains, but with a shop we have gone far beyond that. We started, and then came the shop, but now it's really a conglomerate of many parts. That means we have a marketplace, we have cooperations, we have everything to care for the patient in the complete journey of their healthcare history. That's why the 'care' because we really want to take care of the patient in totality, from aspirin to the G-BA, everything is included, including patient programs, cooperation with pharma. And that no longer fits with 'shop', so we said we need a brand that envelops the whole thing. And because we have the Red points, that's our program for customers, we said okay, and then pharmacy because at our core and heart we are and remain a pharmacy, but it's a large platform, an e-health platform with which we are entering.
H
Host2:02
You've had time to get used to it. Do you think customers might be confused, or is it an established brand name that people know from marketing? Do you think there will be some confusion at first?
T
Theresa Holler2:15
We are doing it gradually. That means we have already switched from Pramaccia to Shop-Apotheke in Italy, and that went surprisingly well. Nevertheless, it will be a journey that gives customers time to get used to it over some time. It starts with the colors changing, the font changes, and so over time the customer is slowly taken along, and then at some point the name changes, but by then customers have probably already gotten used to it. The rest remains the same, so the service remains the same, the idea remains the same, and then I think customers will adapt to the name.
H
Host2:55
Speaking of e-prescription, that's a somewhat longer process, it has been postponed many times. When do you expect it now, and what exactly does that mean?
T
Theresa Holler3:07
I can say from my own history: 21 years ago when we started, we did it because of the e-prescription. That was 21 years ago. This morning we got good news that it should become mandatory next year. For us, that's important because we always say the customer should be guided as easily as possible through their health or illness. The paper prescription in an envelope is a point where convenience breaks. So the e-prescription is really about giving the customer convenience, so that in their journey they are comfortable and, depending on their illness (some people have difficulty going to the pharmacy), they are completely taken care of. The e-prescription is an absolute driver, so we are happy if it comes next year hopefully. But as someone who waited 21 years, they can also wait 22. A few more months won't matter.
H
Host4:11
The next question goes to the CFO, Mr. Ainhorst. When do you expect break-even on net profit, and will you need additional liquidity until then? Thank you.
J
Jasper Ainhorst4:25
Yes, um, I try... if it doesn't work, then... actually the second part of the question: we don't need any more liquidity. Yes, we have a very strong balance sheet and we are very happy with... and what we need, we have that, that's clear. Then the first question from the... two points: we already have a very attractive unit economics model. For us, there is always the possibility: do we want to make a net profit or do we want more growth? Because we can always switch between growth and bottom line. We have the possibility. And the second is: we will look at the numbers in the first quarter. We report in two segments: the DACH segment Germany... 5.2% and the fully loaded... in the last quarter plus 5 million and plus 7%. So it already shows that the net income in Germany was already positive. Yes, our technology allows us to grow very quickly in a very attractive market, but the unit economics... we always have the possibility to be profitable very quickly. And this year 2022, 2023, we also have guidance of neutral free cash flow for the first time for a European pharmacy. So we want to continue to grow at double-digit rates between 10 and 20%. So quickly, but we don't need more cash. That's because we have the possibility we now have.
H
Host6:34
Yes, but let's talk about growth. What growth do you expect in the coming years?
T
Theresa Holler6:38
Always the best... but when you look at the penetration numbers in the countries, there are still so many opportunities. So we don't have an exact guidance, I can't give a specific number because we haven't committed to that, but I can say many more years of double-digit growth. That is our ambition, that is certain, and that is definitely possible. Double-digit. It's really wonderful to work here.
H
Host7:30
Ms. Holler, speaking of growth, but also consolidation within the industry. Are there plans? Are you eyeing acquisitions?
T
Theresa Holler7:30
As we have always said, we have grown organically. Yes, we have made acquisitions like Smart Patient, always acquisitions that complemented us. I think acquisitions can never be ruled out, but it's not our focus. So it's not that we are looking at what we could buy. Our core is to grow from within our organization, and we have now reached a size where you can see that many things match together. We are entering a phase where the marketplace and the core business harmonize, I think, sensationally. And I think now it's more about ensuring that what we have is stable for the future and pushing it forward properly. And yes, if there is an acquisition that makes sense, always, but just buying to become bigger organically or to grow is not our approach.
H
Host8:33
What can investors generally expect from Redcare Pharmacy in the coming years? What can they expect?
T
Theresa Holler8:33
A stable, growing pharmacy that always focuses on the customer, always has the customer in focus, and all ways... we think in use cases, we always look at what the use cases are for the customers. And if that matches, the customer comes, the customer stays. We have a retention rate of over 80%. So the customer we once have stays. Therefore, I would say all investors can look forward to a long story with us.
H
Host9:04
Thank you very much for the interview. Dear viewers, that's the view on this day. From now on, it's no longer Shop-Apotheke, you have to get used to it a bit, Redcare Pharmacy. Thanks for watching, see you next time, take care, bye.